Yaxin Wu1,2, Jiao Wu1,2, Ting Chen1,2, Qing Li1,2, Wei Peng1,2, Huan Li1,2, Xiaowei Tang1, Xiangsheng Fu3,4. 1. Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China. 2. Endoscopy Center, The Affiliated Hospital of Southwest Medical University, Street Taiping 25#, Luzhou, 646000, Sichuan, China. 3. Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China. drfuxs@gmail.com. 4. Endoscopy Center, The Affiliated Hospital of Southwest Medical University, Street Taiping 25#, Luzhou, 646000, Sichuan, China. drfuxs@gmail.com.
Abstract
BACKGROUND: The underlying pathogenic mechanism of Fusobacterium nucleatum in the carcinogenesis of colorectal cancer has been poorly understood. METHODS: Using C57BL/6-ApcMin/+ mice, we investigated gut microbial structures with F. nucleatum, antibiotics, and Toll-like receptor 4 (TLR4) antagonist TAK-242 treatment. In addition, we measured intestinal tumor formation and the expression of TLR4, p21-activated kinase 1 (PAK1), phosphorylated-PAK1 (p-PAK1), phosphorylated-β-catenin S675 (p-β-catenin S675), and cyclin D1 in mice with different treatments. RESULTS: Fusobacterium nucleatum and antibiotics treatment altered gut microbial structures in mice. In addition, F. nucleatum invaded into the intestinal mucosa in large amounts but were less abundant in the feces of F. nucleatum-fed mice. The average number and size of intestinal tumors in F. nucleatum groups was significantly increased compared to control groups in ApcMin/+ mice (P < 0.05). The expression of TLR4, PAK1, p-PAK1, p-β-catenin S675, and cyclin D1 was significantly increased in F. nucleatum groups compared to the control groups (P < 0.05). Moreover, TAK-242 significantly decreased the average number and size of intestinal tumors compared to F. nucleatum groups (P < 0.05). The expression of p-PAK1, p-β-catenin S675, and cyclin D1 was also significantly decreased in the TAK-242-treated group compared to F. nucleatum groups (P < 0.05). CONCLUSIONS: Fusobacterium nucleatum potentiates intestinal tumorigenesis in ApcMin/+ mice via a TLR4/p-PAK1/p-β-catenin S675 cascade. Fusobacterium nucleatum-induced intestinal tumorigenesis can be inhibited by TAK-242, implicating TLR4 as a potential target for the prevention and therapy of F. nucleatum-related colorectal cancer.
BACKGROUND: The underlying pathogenic mechanism of Fusobacterium nucleatum in the carcinogenesis of colorectal cancer has been poorly understood. METHODS: Using C57BL/6-ApcMin/+ mice, we investigated gut microbial structures with F. nucleatum, antibiotics, and Toll-like receptor 4 (TLR4) antagonist TAK-242 treatment. In addition, we measured intestinal tumor formation and the expression of TLR4, p21-activated kinase 1 (PAK1), phosphorylated-PAK1 (p-PAK1), phosphorylated-β-catenin S675 (p-β-catenin S675), and cyclin D1 in mice with different treatments. RESULTS:Fusobacterium nucleatum and antibiotics treatment altered gut microbial structures in mice. In addition, F. nucleatum invaded into the intestinal mucosa in large amounts but were less abundant in the feces of F. nucleatum-fed mice. The average number and size of intestinal tumors in F. nucleatum groups was significantly increased compared to control groups in ApcMin/+ mice (P < 0.05). The expression of TLR4, PAK1, p-PAK1, p-β-catenin S675, and cyclin D1 was significantly increased in F. nucleatum groups compared to the control groups (P < 0.05). Moreover, TAK-242 significantly decreased the average number and size of intestinal tumors compared to F. nucleatum groups (P < 0.05). The expression of p-PAK1, p-β-catenin S675, and cyclin D1 was also significantly decreased in the TAK-242-treated group compared to F. nucleatum groups (P < 0.05). CONCLUSIONS:Fusobacterium nucleatum potentiates intestinal tumorigenesis in ApcMin/+ mice via a TLR4/p-PAK1/p-β-catenin S675 cascade. Fusobacterium nucleatum-induced intestinal tumorigenesis can be inhibited by TAK-242, implicating TLR4 as a potential target for the prevention and therapy of F. nucleatum-related colorectal cancer.
Authors: Masayuki Fukata; Limin Shang; Rebeca Santaolalla; John Sotolongo; Cristhine Pastorini; Cecilia España; Ryan Ungaro; Noam Harpaz; Harry S Cooper; Greg Elson; Marie Kosco-Vilbois; Julia Zaias; Maria T Perez; Lloyd Mayer; Arunan S Vamadevan; Sergio A Lira; Maria T Abreu Journal: Inflamm Bowel Dis Date: 2010-11-15 Impact factor: 5.325
Authors: Julian R Marchesi; Bas E Dutilh; Neil Hall; Wilbert H M Peters; Rian Roelofs; Annemarie Boleij; Harold Tjalsma Journal: PLoS One Date: 2011-05-24 Impact factor: 3.240
Authors: Edgar Torres-Maravilla; Anne-Sophie Boucard; Amir Hossein Mohseni; Sedigheh Taghinezhad-S; Naima G Cortes-Perez; Luis G Bermúdez-Humarán Journal: Microorganisms Date: 2021-05-10
Authors: Jawad Abed; Naseem Maalouf; Abigail L Manson; Ashlee M Earl; Lishay Parhi; Johanna E M Emgård; Michael Klutstein; Shay Tayeb; Gideon Almogy; Karine A Atlan; Stella Chaushu; Eran Israeli; Ofer Mandelboim; Wendy S Garrett; Gilad Bachrach Journal: Front Cell Infect Microbiol Date: 2020-08-07 Impact factor: 5.293